Testosterone and the Prostate: The Evidence So Far

European Urology, Supplements

Volumn 6, Issue 17, 2007, Pages 874-878

  Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Prostate; Prostate cancer; Testosterone; Testosterone deficiency syndrome; Testosterone replacement therapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ENANTATE;

CANCER GROWTH; CASTRATION; CELL FUNCTION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; REVIEW; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE DEFICIENCY SYNDROME;

EID: 34548778632     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.08.003     Document Type: Review

References (31)

1. US Institute of Medicine. In: Liverman C.T., and Blazer D.G. (Eds). Testosterone and aging (2004), Academic Press, National Washington, DC
2. Rhoden E.L., and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350 (2004) 482-492
3. Bhasin S., Singh A.B., Mac R.P., Carter B., Lee M.I., and Cunningham G.R. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 24 (2003) 299-311
4. Ebert T., Jockenhövel F., Morales A., and Shabsigh R. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol 47 (2005) 137-146
5. Tubaro A. Testosterone and prostate Cancer. Eur Urol 51 (2007) 293-295
6. Barqawi A., and Crawford E.D. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?. Int J Impot Res 18 (2006) 323-328
7. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50 (2006) 935-939
8. Huggins C., and Hodges C.V. Studies on prostatic cancer. I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
9. Huggins C. Endocrine-induced regression of cancers. Cancer Res 27 (1967) 439-443
10. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
11. Fowler J.E., and Whitmore W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126 (1981) 372-375
12. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296 (2006) 2351-2361
13. Eaton N.E., Reeves G.K., Appleby P.N., and Key T.J. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80 (1999) 930-934
14. Persons J.K., Carter H.B., Platz E.A., Wright E.J., Landis P., and Metter E.J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14 (2005) 2257-2260
15. Mohr B.A., Feldman H.A., Kalish L.A., Longcope C., and McKinlay J.B. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 57 (2001) 930-935
16. Heikkila R., Aho K., Heliiovaara M., et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86 (1999) 312-315
17. Chen C., Weiss N.S., Stanczyk F.Z., et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 12 (2003) 1410-1416
18. Platz E.A., Leitzmann M.F., Rifai N., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 (2005) 1262-1269
19. Stattin P., Lumme S., Tenkanen L., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108 (2004) 418-424
20. Severi G., Morris H.A., MacInnis R.J., et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 86-91
21. Gann P.H., Hennekens C.H., Ma J., Longcope C., and Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1996) 1118-1126
22. Isom-Batz G., Bianco Jr. F.J., Kattan M.W., Mulhall J.P., Lilja H., and Eastham J.A. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173 (2005) 1935-1937
23. San Francisco I.F., Regan M.M., Dewolf W.C., and Olumi A.F. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341-1346
24. Imamoto T., Suzuki H., Fukasawa S., et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol 47 (2005) 308-312
25. Behre H.M., Bohmeyer J., and Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 40 (1994) 341-349
26. Cooper C.S., Perry P.J., Sparks A.E., MacIndoe J.H., Yates W.R., and Williams R.D. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 159 (1998) 441-443
27. Bhasin S., Woodhouse L., Casaburi R., et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281 (2001) E1172-E1181
28. Institute of Medicine. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Testosterone and aging: clinical research directions (2003), National Academies Press, Washington, DC
29. Miner M.M., and Seftel A.D. Testosterone and ageing: what have we learnt since the Institute of Medicine report and what lies ahead?. Int J Clin Pract 61 (2007) 622-632
30. Morales A. Testosterone and prostate health: debunking myths demands evidence, caution, and good clinical judgment. Eur Urol 50 (2006) 895-897
31. Nieschlag E., Swerdloff R., Behre H.M., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM and EAU recommendations. Int J Androl 28 (2005) 125-127